PHILADELPHIA — (Apr. 5, 2019) — A new approach for delivery of DNA-encoded monoclonal antibodies (DMAbs) has been reported by Wistar scientists and their collaborators. This new technology allows d…
PHILADELPHIA — (March 6, 2019) — Researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr Virus (EBV), the virus that causes infectious mononucleos…
Philadelphia and San Jose, Calif. – (Feb. 21, 2019) – The Wistar Institute has extended its collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the b…
PHILADELPHIA — (Feb. 18, 2019) — Researchers at The Wistar Institute have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release …
PHILADELPHIA — (Feb. 15, 2019) — David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center, and the W.W. Smith Charitable Trust Professor in Cancer Resear…
PHILADELPHIA — (Feb. 14, 2019) — The Wistar Institute was awarded two grants totaling more than $128,000 from the Pennsylvania Department of Labor & Industry to support the Institute’s training…
PHILADELPHIA and TAMPA, Fla. — (Feb. 14, 2019) — Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma mor…
PHILADELPHIA — (Feb. 11, 2019) — The Wistar Institute announces that it was awarded more than $16M in federal research funds in support of its groundbreaking research in cancer, immunology and infe…
PHILADELPHIA — (Feb. 7, 2019) — A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South…
CAMBRIDGE, MA and PHILADELPHIA — January 30, 2019 — Cullinan Oncology, LLC and The Wistar Institute today announced an agreement to accelerate the development of VK-2019, a novel EBNA1 (Epstein-Bar…
